This article is more than 5 years old. Information may no longer be current.
Healio Minute Friday, March 14, 2014 Edition: CMS wants your ideas, Pfizer appeals Celebrex ruling, stroke treatment delays tallied
What just happened in medicine and why do you care?
Click Here to Manage Email Alerts
CMS seeks guidance on strategies, resources for practice transformation
Healio.com/Regulatory New ideas will be necessary to achieve a large-scale transformation of physician practices in support of the “triple aim” of better care and better health at lower costs. Analysis by Ted Lotchin of Arnold & Porter LLP. Read more.
Pfizer to appeal court ruling invalidating Celebrex reissue patent
Healio.com/RheumatologyPfizer had brought action against generic manufacturers in a trial that was scheduled to begin March 19 for infringement of the reissue patent. Read more.
Each 15-minute delay in stroke treatment linked to month loss of healthy life
Healio.com/Cardiology Greatest gains were achieved by the youngest patients with the longest life expectancies after stroke, and women achieved slightly more gains than men. Read more.
Infliximab failed to reduce treatment resistance of Kawasaki disease
Healio.com/Infectious Disease The addition of infliximab to initial therapy did not affect treatment resistance, but administration of infliximab shortened the duration of fever, eliminated the risk of infusion reactions if given before IV immunoglobulin, and more rapidly reduced inflammation. Read more.
Routine childhood vaccination programs result in substantial cost savings
Healio.com/Pediatrics The program averted $6.7 billion in direct costs and $7.5 billion in societal costs, researchers say, plus a savings of 13.5 billion from the payers’ perspective and $68.8 billion from societal perspectives. Read more.